Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

Main Inclusion Criteria:

1. Male or female children aged 4 through 11 years;
2. Physician-diagnosis of peanut allergy or children with a well documented medicalhistory of IgE-mediated symptoms after ingestion of peanut and currently following astrict peanut-free diet, but without a physician diagnosis;
3. Peanut-specific IgE level (ImmunoCAP system) >0.7 kU/L;
4. Positive peanut skin prick test (SPT) with a largest wheal diameter:

• ≥6 mm for children 4 through 5 years of age at Visit 1,
• ≥8 mm for children 6 years and above at Visit 1;

5. Positive DBPCFC at ≤300 mg peanut protein.

Main Exclusion Criteria:

1. History of severe anaphylaxis to peanut with any of the following symptoms:hypotension, hypoxia, neurological compromise (collapse, loss of consciousness orincontinence);
2. Generalized dermatologic disease
3. Diagnosis of mast cell disorders, including mastocytosis or uricaria pigmentosa aswell as hereditary or idiopathic angioedema;
4. Diagnosis of asthma that fulfills any of the following criteria:

• Uncontrolled persistent asthma as defined by National Asthma Education andPrevention Program Asthma guidelines 2007 or by Global Initiative for Asthmaguidelines 2015,
• Asthma treated with either a high daily high dose of inhaled corticosteroid orwith a combination therapy of a medium or high daily dose of inhaledcorticosteroid with a long acting inhaled β2 agonist or with a combinationtherapy of a high daily dose of inhaled corticosteroid with a long acting inhaled β2 agonist. Asthmatic subjects treated with a medium daily dose of inhaledcorticosteroids are eligible. Intermittent asthmatic subjects who requireintermittent use of inhaled corticosteroids for rescue are also eligible,
• Two or more systemic corticosteroid courses for asthma in the past year or 1 oralcorticosteroid course for asthma within 3 months prior to Visit 1, or duringscreening period,
• Prior intubation/mechanical ventilation for asthma within 1 year prior to Visit 1, or during screening;

5. Receiving β-blocking agents, angiotensin-converting enzyme inhibitors,angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressanttherapy;
6. Received anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) orany biologic immunomodulatory therapy within 1 year prior to Visit 1, during screeningperiod or during study participation;
7. Use of systemic long-acting corticosteroids within 12 weeks prior to Visit 1 and/oruse of systemic short-acting corticosteroids within 4 weeks prior to Visit 1 or duringscreening;
8. Prior or concomitant history of any immunotherapy to any food;
9. Receiving or planning to receive any aeroallergen immunotherapy during theirparticipation in the study. Aeroallergen immunotherapy must be discontinued at thetime of Visit 1;
10. Any disorder in which epinephrine is contraindicated such as coronary artery disease,uncontrolled hypertension, or serious ventricular arrhythmias.